Vertical: CNMBase Year: 2025
Market Size (2025)
$56.00M
Projected (2032)
$78.01M
CAGR (2022–2032)
4.9%
Key Players
9+
Market Overview
The Global Halofuginone Market was valued at USD 56.00 Million in 2025 and is projected to reach USD 78.01 Million by 2032, registering a CAGR of 4.85% during the forecast period 2026–2032. Over the historic period, the market increased from USD 48.57 Million in 2022 to USD 53.41 Million in 2024. Between 2025 and 2032, the market is expected to add USD 22.01 Million in absolute value.
Halofuginone is a synthetic quinazolinone derivative of febrifugine, an alkaloid originally isolated from the plant Dichroa febrifuga. In animal health it is used in two commercial forms: halofuginone hydrobromide, incorporated into medicated feed premixes as an anticoccidial for broiler chickens and turkeys, and halofuginone lactate, supplied as an oral solution for the prevention and reduction of diarrhoea caused by Cryptosporidium parvum in newborn calves. The market is therefore shaped by two distinct demand pools: the intensive poultry sector, where coccidiosis control is a routine production input, and the dairy and beef calf-rearing sector, where cryptosporidiosis is one of the most common causes of neonatal scour.
Market growth is supported by rising global poultry meat output, the continued shift away from antibiotic growth promoters towards structured coccidiosis-control programmes, the high prevalence of Cryptosporidium in pre-weaned calves, and the wider availability of generic halofuginone lactate products in Europe. Growth is moderated by the narrow safety margin of the molecule, competition from ionophores, other chemical anticoccidials and vaccines, and the regulatory cost of maintaining authorisations and residue compliance.
Key Findings
Livestock: Poultry was the largest segment in 2025 at USD 33.60 Million (60.00% share) and is also the fastest-growing segment, with a CAGR of 5.22% during 2026–2032.
Physical form: Premix held the largest share in 2025 at USD 42.00 Million (75.00%), while Oral Solution is the fastest-growing form, with a CAGR of 5.90%.
Region: Asia Pacific was the leading region in 2025 at USD 23.52 Million (42.00% share). Middle East & Africa is the fastest-growing region, with a CAGR of 5.83%.
Country: China was the leading country in 2025 at USD 10.82 Million, while UAE is the fastest-growing country, with a CAGR of 6.78% during 2026–2032.
Europe profile: Europe is the only region in which Calves & Others (USD 4.54 Million) exceeded Poultry (USD 3.86 Million) in 2025, reflecting the long-established use of halofuginone lactate oral solutions for calf cryptosporidiosis in the region.
Segmentation Summary
The market is segmented by livestock into Poultry and Calves & Others, and by physical form into Premix and Oral Solution. The two segmentations are closely linked. Premix products are used almost entirely as in-feed anticoccidials for poultry, while oral solutions are the established dosage form for neonatal calves. Premix accounted for 75.00% of the market in 2025 and is projected to reach USD 57.06 Million by 2032. Oral Solution, valued at USD 14.00 Million in 2025, is projected to grow faster, at a CAGR of 5.90%, supported by generic availability and broader veterinary awareness of cryptosporidiosis management in calves.
By livestock, Poultry is expected to grow from USD 33.60 Million in 2025 to USD 48.02 Million in 2032, while Calves & Others is projected to increase from USD 22.40 Million to USD 29.99 Million, at a CAGR of 4.26%.
Competitive Landscape Summary
The market is moderately consolidated at the originator level and fragmented at the generic level. MSD Animal Health (Merck & Co., Inc.) holds the originator calf product, Halocur, which has been authorised in the European Union since 1999. Huvepharma owns the Stenorol brand of halofuginone hydrobromide premix for poultry, which was re-authorised in the European Union in January 2024 under Implementing Regulation (EU) 2024/231 and is approved in the United States under 21 CFR 558.265. Generic halofuginone lactate oral solutions are marketed by Virbac (Kriptazen), Emdoka (Halagon), Huvepharma (Stenorol Crypto), Laboratorios Karizoo (Halofusol) and Industrial Veterinaria (Cryptisel). Active pharmaceutical ingredient supply includes manufacturers in China. Competition centres on regulatory approvals, price, dosing convenience, distribution reach and technical support to veterinarians and integrators.
Challenges and Opportunities
The principal challenges are the narrow therapeutic index of halofuginone in calves, where toxicity can occur at about twice the therapeutic dose, its toxicity to fish and aquatic organisms, and restrictions on use in laying hens and waterfowl. Substitution pressure is rising from coccidiosis vaccines in poultry and, since 2023, from the first vaccine against C. parvum for calves, administered to pregnant cows. Opportunities exist in the expansion of intensive poultry and dairy production in Asia Pacific, Latin America and the Middle East & Africa, the use of halofuginone in rotation and shuttle programmes to manage anticoccidial resistance, and the extension of generic oral solutions into markets where calf cryptosporidiosis treatment options remain limited.
Future Outlook
The market is expected to grow steadily, rising from USD 58.72 Million in 2026 to USD 78.01 Million in 2032. Asia Pacific will remain the largest regional market, reaching USD 33.42 Million by 2032, while the Middle East & Africa and Latin America are expected to grow faster than the global average. Halofuginone is likely to remain a niche but established tool in both poultry coccidiosis control and calf cryptosporidiosis management, with demand linked to livestock production volumes, the pace of antibiotic-reduction policies, and the uptake of vaccines that may complement or partly substitute chemical control.
The Halofuginone Market market is projected to grow at a CAGR of 4.9% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Halofuginone (7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone) is a halogenated derivative of febrifugine. It acts against the developing stages of apicomplexan parasites, including the sporozoite and merozoite stages of Eimeria species in poultry and Cryptosporidium parvum in calves. Its antiparasitic activity is linked to inhibition of prolyl-tRNA synthetase, which interrupts parasite protein synthesis.
For the purpose of this study, the Global Halofuginone Market comprises the sales value of veterinary products in which halofuginone is the active substance, measured at manufacturer level. This includes:
Halofuginone hydrobromide premixes and medicated feed articles used as anticoccidials in poultry, primarily broiler chickens, replacement chickens and turkeys.
Halofuginone lactate oral solutions used for the prevention and reduction of diarrhoea caused by Cryptosporidium parvum in newborn calves, together with use in other young ruminants where permitted under veterinary prescription.
Branded originator products and generic formulations sold through veterinary, feed-mill and integrator channels.
The study excludes:
Halofuginone investigated for human therapeutic applications, such as fibrotic disorders and muscular dystrophy research.
Other anticoccidials and anti-cryptosporidial products, including ionophores, other chemical coccidiostats, paromomycin and vaccines, which are considered competing products.
Value added downstream in complete medicated feed, and services such as diagnostics and veterinary consultation.
Research Objectives
To estimate the size of the global halofuginone market in USD Million for the historic years 2022–2024 and the base year 2025, and to forecast it for 2026–2032.
To analyse the market by livestock (Poultry; Calves & Others) and by physical form (Premix; Oral Solution), identifying the largest and fastest-growing segments.
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.
To identify the drivers, restraints, opportunities and trends that influence demand for halofuginone in poultry coccidiosis control and calf cryptosporidiosis management.
To evaluate the regulatory framework governing halofuginone, including feed additive authorisations, veterinary medicine approvals, maximum residue limits and withdrawal periods.
To examine the value chain, competitive forces and macro-environmental factors affecting the market.
To profile the competitive structure of the market, including originator and generic suppliers, and to track key developments from 2022 onward.
To assess the impact of substitute technologies, particularly coccidiosis vaccines and the C. parvum vaccine for calves, on the long-term outlook for halofuginone.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process combining secondary research, primary research, market size estimation and data validation. The process began with defining the market scope and segmentation, followed by collection of data on livestock populations, product approvals, pricing, dosing regimens and company activity. Market estimates were then built using top-down and bottom-up approaches, triangulated, and validated through primary inputs from industry participants. The final dataset was used to prepare the historic estimates for 2022–2024, the base-year value for 2025 and the forecasts for 2026–2032.
Stage 1 – Scoping: definition of the product, segmentation, geography and timeline.
Stage 2 – Secondary research: collection of published data from regulatory, statistical, industry and company sources.
Stage 3 – Primary research: discussions with supply-side and demand-side participants to validate assumptions.
Stage 4 – Estimation and forecasting: top-down and bottom-up modelling with data triangulation.
Stage 5 – Validation and reporting: consistency checks across segments, regions and countries, and preparation of the report.
Secondary Research
Secondary research was used to establish the regulatory status of halofuginone products, the size of the target animal populations and the structure of the supply base. The main source types were:
Regulatory bodies and product registers: the European Medicines Agency (EPARs and MRL reports), the Union Product Database for veterinary medicines, EUR-Lex for feed additive authorisations, the U.S. Food and Drug Administration (Animal Drugs @ FDA and the Code of Federal Regulations), the UK Veterinary Medicines Directorate, and the Canadian Food Inspection Agency.
Scientific and risk-assessment bodies: European Food Safety Authority (EFSA) FEEDAP opinions on halofuginone hydrobromide, and peer-reviewed literature on coccidiosis and cryptosporidiosis.
Government agricultural statistics: USDA Foreign Agricultural Service and Economic Research Service data on poultry production, FAO statistics on livestock and poultry, and national agriculture ministry publications.
Industry associations: national and regional poultry, dairy and animal health industry associations, including animal health manufacturers’ associations.
Company sources: annual reports, investor presentations, product literature and press releases of animal health companies and API manufacturers.
Trade journals and paid databases: veterinary and feed industry publications, trade data and commercial company databases.
Primary Research
Primary research was conducted through in-depth discussions with participants across the value chain. The objectives were to validate market size estimates, understand pricing and dosing practices, assess segment and regional splits, and capture qualitative insights on demand drivers, competition and regulation.
Supply side: product managers and commercial executives at animal health companies, API manufacturers, premix producers and distributors.
Demand side: poultry veterinarians, nutritionists at integrated poultry companies and feed mills, dairy and cattle veterinarians, and calf-rearing operators.
Other participants: regulatory consultants and academic researchers in veterinary parasitology.
Market Size Estimation
Bottom-up approach: The market was estimated by country from the volume of halofuginone consumed in each application. For poultry, the number of broilers and turkeys produced, the share of flocks on halofuginone-containing programmes, inclusion rates and treatment duration were used to estimate premix demand. For calves, the number of calves born, the share treated for cryptosporidiosis and the dose per treatment course were used to estimate oral solution demand. Volumes were multiplied by average manufacturer-level prices to derive value, and country estimates were aggregated to regional and global totals.
Top-down approach: The global animal health and anticoccidial markets were used as reference points, and the share attributable to halofuginone was estimated using company revenue information, product portfolio analysis and expert inputs. This total was then allocated to regions, countries and segments.
Data triangulation: Results from both approaches were compared, and differences were reconciled using primary research inputs. Final values were checked so that segment values sum to the total for each year and each segmentation total matches the overall market total.
Forecasting Methodology
Forecasts for 2026–2032 were developed using the base-year estimates and the expected trajectory of the factors that drive demand. The main factors considered were:
Growth in poultry meat production and in cattle and dairy herd sizes by country.
Changes in coccidiosis-control practices, including the shift from antibiotic growth promoters, rotation and shuttle programmes, and vaccine adoption.
Prevalence of cryptosporidiosis in calves and the uptake of treatment and prevention products.
Regulatory developments, including authorisations, re-authorisations, residue limits and withdrawal periods.
Pricing trends, including the effect of generic entry and API cost movements.
Macroeconomic conditions, including feed costs, farm profitability and currency movements.
Each factor was assessed for its expected impact over the short, medium and long term, and growth rates were applied at country and segment level before being aggregated.
Assumptions and Limitations
All values are expressed in USD Million at manufacturer-level prices. Currency effects are based on average exchange rates.
Regulatory status of halofuginone products in each country is assumed to remain broadly unchanged during the forecast period, except where developments are already known.
No major disruption in API supply or significant change in the safety profile of halofuginone is assumed.
Livestock production is assumed to follow current outlooks, without large-scale disease events that significantly reduce animal populations for extended periods.
Country-level data on halofuginone consumption is not published directly, so estimates rely on indirect indicators and expert inputs.
Off-label and cascade use in species other than poultry and calves is difficult to quantify and is included in the Calves & Others segment based on estimates.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global halofuginone market has a two-tier structure. At the originator level it is consolidated: MSD Animal Health, through Intervet International B.V., holds the original calf product, Halocur, and Huvepharma holds the Stenorol brand of halofuginone hydrobromide for poultry, including its U.S. approvals and its 2024 EU re-authorisation. At the generic level, particularly for halofuginone lactate oral solutions in Europe, the market is fragmented, with several mid-sized and specialist veterinary generics companies holding authorisations. API supply is concentrated among a limited number of chemical manufacturers, including companies in China.
Competition is based on regulatory authorisations and their geographic coverage, price, dosing convenience, product quality and supply reliability, and technical support to veterinarians, nutritionists and integrators. Because the active substance and concentration are identical across oral solution products, differentiation relies on dosing devices, pack sizes, brand recognition and distribution reach. In poultry, halofuginone also competes indirectly with ionophores, other chemical anticoccidials and vaccines marketed by larger animal health companies.
Key Player Positioning
Leaders: MSD Animal Health and Huvepharma. MSD Animal Health, the animal health division of Merck & Co., Inc., reported animal health sales of USD 6,354 million in 2025 and combines Halocur with Bovilis Cryptium, giving it both treatment and prevention products for calf cryptosporidiosis. Huvepharma, a Bulgarian animal health company that reported sales of USD 731 million in 2023, holds Stenorol premix for poultry and Stenorol Crypto oral solution for calves, giving it a presence in both segments of the market.
Challengers: Virbac and Emdoka. Virbac, which reported revenue of EUR 1,464.7 million in 2025, markets Kriptazen, a centrally authorised generic oral solution, and has expanded its farm-animal business through acquisitions. Emdoka, a Belgian veterinary generics company, holds the centrally authorised Halagon and has extended its reach through distribution partnerships, including with Bimeda-MTC in Canada.
Niche players: Laboratorios Karizoo (Alivira), Industrial Veterinaria (INVESA), Bimeda, Chongqing VPON Pharmaceutical and Jiangsu Lingyun Pharmaceutical. Karizoo and INVESA hold Spanish-led decentralised authorisations for generic oral solutions. Bimeda participates through distribution. Chongqing VPON and Jiangsu Lingyun supply halofuginone as an active pharmaceutical ingredient.
Threat of New Entrants (Low):
New suppliers must obtain veterinary medicine or feed additive authorisations, supported by residue, safety and efficacy data.
The market is small in absolute value, which limits the return on the investment needed for registration.
Established brands such as Halocur and Stenorol benefit from long-standing recognition among veterinarians and integrators.
Bargaining Power of Suppliers (Medium):
Halofuginone API is produced by a limited number of manufacturers, which concentrates supply.
Changing API source in regulated markets requires a regulatory variation, which increases switching costs.
Large animal health companies can partly offset supplier power through multiple qualified sources.
Bargaining Power of Buyers (Medium):
Integrated poultry companies and feed mills buy in large volumes and can switch between anticoccidials.
In the calf segment, buyers are more fragmented and rely on veterinary prescription.
Generic competition in oral solutions has increased buyers’ ability to negotiate on price.
Threat of Substitutes (High):
Poultry producers can use ionophores, other chemical anticoccidials or vaccines instead of halofuginone.
For calves, paromomycin products, management measures and a C. parvum vaccine for cows are available.
Antibiotic-free programmes and vaccination trends can shift demand between control methods.
Competitive Rivalry (Medium):
Few companies compete in poultry premixes, while the calf oral solution segment has several generic suppliers.
Competition focuses on price, dosing convenience, distribution reach and technical support.
Product differentiation is limited because generics share the same active substance and concentration.
Threat of New Entrants: Low; New suppliers must obtain veterinary medicine or feed additive authorisations, supported by residue, safety and efficacy data.
Bargaining Power of Suppliers: Medium; Halofuginone API is produced by a limited number of manufacturers, which concentrates supply.
Bargaining Power of Buyers: Medium; Integrated poultry companies and feed mills buy in large volumes and can switch between anticoccidials.
Threat of Substitutes: High; Poultry producers can use ionophores, other chemical anticoccidials or vaccines instead of halofuginone.
Competitive Rivalry: Medium; Few companies compete in poultry premixes, while the calf oral solution segment has several generic suppliers.
Market estimates by geography (2032)
InsightAsia Pacific leads with $33.42M by 2032, while Middle East & Africa is projected to grow fastest at a 5.8% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $8.93M | $10.94M | $13.46M | 4.2% | 17% |
| Europe | $7.52M | $9.06M | $11.00M | 3.9% | 14% |
| Asia Pacific | $20.12M | $26.05M | $33.42M | 5.2% | 43% |
| Latin America | $8.69M | $11.13M | $14.30M | 5.1% | 18% |
| Middle East & Africa | $3.32M | $4.39M | $5.83M | 5.8% | 7% |
| Total | $48.57M | $61.57M | $78.01M | 4.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$78.01M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $48.02M | 5.3% | 62% |
| Calves & Others | $29.99M | 4.2% | 38% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Halofuginone Market covering market dynamics, competitive landscape, and strategic outlook.
The Halofuginone Market market is projected to reach $78.01M by 2032, growing at 4.9% CAGR. The Poultry segment holds the largest share.
Demand for halofuginone is driven by two production systems with different economics. In poultry, halofuginone hydrobromide is one of several in-feed tools available to control coccidiosis, a disease caused by Eimeria species that reduces weight gain and feed efficiency. A 2020 study published in Veterinary Research estimated the global cost of coccidiosis in chickens at about £10.4 billion at 2016 prices. In cattle, halofuginone lactate is one of very few licensed medicines for cryptosporidiosis, which is a major cause of diarrhoea in calves under four weeks of age. This chapter analyses the factors that promote and inhibit growth in these two applications.
Market Growth Factor Analysis
The table below assesses five macro and five micro factors that influence the market. Each factor is classified by impact type and assigned an impact score out of 10 for three time periods. The impact scores are analyst assessments based on secondary and primary research, where a higher score indicates a stronger influence on the market.
Rising Global Poultry Production
Poultry is the fastest-growing source of animal protein globally, and the volume of birds produced is the main determinant of anticoccidial demand. According to the USDA Foreign Agricultural Service, global chicken meat production is estimated at 108.4 million tonnes in 2025 and forecast at 112.4 million tonnes in 2026, with growth led by China, Brazil, the United States and the European Union. Because coccidiosis is present wherever birds are reared on litter, virtually every intensive broiler and turkey flock requires a coccidiosis-control programme, whether based on in-feed products, vaccines or a combination. Halofuginone hydrobromide premix is used in broilers and turkeys at low inclusion rates, typically 2–3 mg per kg of complete feed, and is approved in major producing markets such as the United States, the European Union and Canada. As integrated poultry companies expand capacity in Asia Pacific, Latin America and the Middle East, the number of birds requiring anticoccidial protection increases proportionately. This underpins the Poultry segment, which accounted for 60.00% of the market in 2025.
Prevalence of Cryptosporidiosis in Calves
Cryptosporidium parvum is one of the most common infectious causes of diarrhoea in calves during the first weeks of life. A global meta-analysis published in 2025, covering 248 publications and more than 124,000 cattle, reported a pooled Cryptosporidium prevalence of 37.5% in pre-weaned cattle, with C. parvum accounting for most species-identified infections. In the United Kingdom, C. parvum has been the most commonly diagnosed cause of infectious calf scour in government surveillance data. Infection leads to dehydration, reduced growth and, in severe cases, mortality, and oocysts are highly resistant to common disinfectants. Few licensed medicines are available for this disease, and halofuginone lactate has been the main authorised option in Europe since Halocur was approved in 1999. A 2021 meta-analysis in the journal Parasitology found that halofuginone treatment started within the first days of life significantly reduced oocyst shedding, diarrhoea and mortality. These factors sustain demand in the Calves & Others segment, valued at USD 22.40 Million in 2025.
Shift Away from Antibiotic Growth Promoters
Regulatory restrictions and consumer demand have reduced the use of medically important antibiotics in livestock. The European Union banned antibiotic growth promoters in 2006, the United States moved medically important antimicrobials in feed under veterinary oversight through the Veterinary Feed Directive, and China’s Ministry of Agriculture and Rural Affairs removed growth-promoting antibiotics from feed from 2020 under Announcement 194. In the United States, an industry survey of 2021 practice found that 59% of broilers were raised under “no antibiotics ever” programmes, and that 55% were vaccinated against coccidiosis. These changes have increased the importance of non-antibiotic coccidiosis-control tools. Halofuginone is a synthetic chemical anticoccidial rather than an ionophore antibiotic, which allows it to be used in rotation or shuttle programmes, including programmes that limit ionophore use. The shift therefore supports structured, multi-product control strategies in which halofuginone has a defined role, particularly in turkeys and in programmes designed to manage parasite sensitivity.
Generic Availability of Oral Solutions
Following the expiry of exclusivity on the originator product, several generic halofuginone lactate 0.5 mg/ml oral solutions were authorised in Europe between 2016 and 2021. These include Halagon (Emdoka, centrally authorised in 2016), Kriptazen (Virbac, 2019), Stenorol Crypto (Huvepharma, 2020), Halofusol (Laboratorios Karizoo, 2020) and Cryptisel (Industrial Veterinaria, 2020–2021). The entry of multiple suppliers has widened distribution, introduced dosing devices such as weight-graduated pumps, and increased price competition, which improves affordability for dairy and suckler farmers. Generic manufacturers have also extended the product into additional markets through distribution partnerships, such as the import of Halagon into Canada by Bimeda-MTC. Broader availability encourages earlier and more consistent use in herds with a history of cryptosporidiosis, supporting the Oral Solution segment, which is projected to grow at a CAGR of 5.90% during 2026–2032, faster than the overall market.
Expansion in Emerging Livestock Markets
Poultry and dairy production are growing faster in Asia Pacific, Latin America and the Middle East & Africa than in mature markets. Middle East & Africa is projected to grow at a CAGR of 5.83% and India at 6.49% during 2026–2032. Food-security programmes in Gulf countries and the growth of integrated poultry companies in India, Southeast Asia and Africa create opportunities for registration and distribution of halofuginone products in markets where coccidiosis and calf scour control are becoming more structured.
Role in Anticoccidial Resistance Management
Repeated use of the same anticoccidial class leads to reduced sensitivity of Eimeria populations. Rotation and shuttle programmes that alternate ionophores, chemical products and vaccines are widely used to preserve efficacy. Halofuginone, as a chemical product with a distinct mode of action, can be positioned within these programmes, particularly in turkey production. The EU requirement for post-market resistance monitoring also generates field data that can support its responsible use.
Integrated Calf-Health Programmes
Rather than replacing treatment entirely, cow vaccination against C. parvum can be combined with management measures and targeted halofuginone use in high-risk herds. Companies with both vaccines and therapeutics can offer integrated calf-health programmes, while generic suppliers can focus on improved dosing devices, pack sizes for large dairy units, and veterinary education on early intervention.
Narrow Safety Margin and Handling Risks
Halofuginone has a narrow therapeutic index. In calves, signs of toxicity may occur at about twice the recommended dose, so accurate dosing based on body weight is essential, and use is not recommended in calves that have had diarrhoea for more than 24 hours or in weak animals. In poultry, product labels restrict use in laying hens and waterfowl. The substance is also a strong skin and eye irritant and skin sensitiser for users, and it is toxic to fish and other aquatic organisms, which requires careful disposal. These characteristics limit its use to specific indications and require veterinary supervision, restraining wider adoption.
Competition from Alternative Control Methods
In poultry, halofuginone competes with ionophores such as monensin, salinomycin, narasin and lasalocid, with other chemical anticoccidials such as nicarbazin, diclazuril, robenidine and decoquinate, and with live coccidiosis vaccines. In calves, it competes with paromomycin-based products, management measures such as colostrum feeding and hygiene, and, since the European Union approval of Bovilis Cryptium in November 2023, with a vaccine given to pregnant cows to protect calves through colostrum. Wider vaccine adoption could reduce the number of animals requiring chemical treatment.
Regulatory and Residue Compliance Costs
Halofuginone is subject to maximum residue limits and withdrawal periods in all major markets. In the European Union, halofuginone lactate is not authorised for animals producing milk for human consumption, and the poultry feed additive authorisation requires post-market monitoring of Eimeria resistance. Maintaining dossiers, conducting residue studies and complying with re-authorisation requirements increase costs for manufacturers and can discourage registration in smaller markets.
Vaccination in both applications: Coccidiosis vaccination in broilers has increased significantly, and a C. parvum vaccine for cows is now approved in the European Union, Great Britain and New Zealand. Halofuginone is increasingly used alongside, rather than instead of, vaccines.
Re-authorisation and stewardship: Regulators are re-evaluating older feed additives. The 2024 EU re-authorisation of halofuginone hydrobromide confirmed its continued availability until 2034 but added conditions such as resistance monitoring and user-safety measures.
API supply concentration: Halofuginone API is produced by a limited number of manufacturers, including suppliers in China. Changes to API sources, such as the supplier changes recorded for Halocur in the United Kingdom in 2023 and 2025, show the importance of supply security.
Price pressure from generics: The number of generic oral solutions in Europe has increased price competition, encouraging suppliers to differentiate through dosing devices, pack sizes and veterinary support.
The halofuginone value chain links specialised chemical synthesis with feed manufacturing and veterinary distribution. Each stage is described below.
Value is concentrated at the API and formulation stages, where regulatory approvals, dossier ownership and manufacturing quality create barriers to entry. In poultry, feed mills and integrators exercise purchasing power because anticoccidials are bought in volume as part of feed programmes. In the calf segment, veterinarians influence product selection, and brand recognition and technical support play a larger role.
Across regions, the regulatory focus is on consumer safety through residue limits and withdrawal periods, user safety, environmental protection and antimicrobial stewardship. In the European Union, the bovine MRLs for halofuginone are 10 µg/kg in muscle, 25 µg/kg in fat and 30 µg/kg in liver and kidney, with an acceptable daily intake of 0.3 µg/kg body weight. For poultry, the 2024 EU authorisation sets a content of 2–3 mg/kg of complete feed and a withdrawal period of three days.
Aug 2022: Bimeda; Acquisition; Acquired Afrivet, a South African animal health company, expanding its presence in Africa.
Jun 2023: MSD Animal Health; Supply Chain; Added a new active substance manufacturer to the Halocur dossier in the United Kingdom.
Nov 2023: MSD Animal Health; Product Approval; Received EU approval for Bovilis Cryptium, the first vaccine against C. parvum, given to pregnant cows to protect calves through colostrum.
Jan 2024: Huvepharma; Regulatory Approval; Halofuginone hydrobromide (Stenorol) re-authorised in the EU under Implementing Regulation (EU) 2024/231 for chickens and turkeys, valid until February 2034.
Apr 2024: Virbac; Acquisition; Acquired Sasaeah, a Japanese animal health company, strengthening its farm-animal presence in Japan.
Jun 2024: Huvepharma; Investment; Invested EUR 7.5 million in Fermentalg, becoming a cornerstone shareholder.
Aug 2024: MSD Animal Health; Product Approval; Received approval from the UK Veterinary Medicines Directorate for Bovilis Cryptium in Great Britain.
Dec 2024: Virbac; Acquisition; Acquired Mopsan, an animal health company in Türkiye.
Mar 2025: MSD Animal Health; Supply Chain; Removed an active substance manufacturing site from the Halocur dossier in the United Kingdom.
Nov 2025: SeQuent Scientific (parent of Alivira); Merger; The National Company Law Tribunal approved the merger of SeQuent Scientific with Viyash.
Dec 2025: Huvepharma; Expansion; Outlined investment plans covering renewable energy, livestock vaccines and growth in Latin America, Asia, Africa and cattle markets.
Jan 2026: MSD Animal Health; Product Approval; Received approval for Bovilis Cryptium in New Zealand.
Political
Government policies on antimicrobial reduction, such as the EU ban on antibiotic growth promoters and China’s 2020 feed antibiotic withdrawal, influence the choice of coccidiosis-control products.
Food-security programmes in the Gulf and other import-dependent regions support domestic poultry and dairy production.
Trade policies and sanitary requirements affect poultry exports from Brazil, the United States and Thailand, and in turn the use of approved feed additives.
Economic
Feed costs account for the majority of poultry production costs, so producers evaluate anticoccidial programmes on cost per bird.
Generic competition has reduced prices of halofuginone lactate oral solutions in Europe.
Currency movements affect import costs of API and finished products in emerging markets.
Social
Rising per capita consumption of poultry meat in Asia, Africa and Latin America increases bird numbers.
Consumer demand for antibiotic-free meat influences coccidiosis-control choices.
Animal welfare expectations encourage prevention of calf diarrhoea and lower calf mortality.
Technological
Development of live coccidiosis vaccines and the first C. parvum vaccine for cows changes the role of chemical control.
Improved dosing devices for oral solutions, such as weight-graduated pumps, support accurate dosing.
Rapid diagnostics for Cryptosporidium help target treatment to affected herds.
Environmental
Halofuginone is toxic to fish and aquatic organisms, requiring controlled disposal of unused product and containers.
Environmental risk assessments form part of EU feed additive and veterinary medicine authorisations.
Cryptosporidium oocysts can contaminate water sources, linking calf health to wider One Health concerns.
Legal
Maximum residue limits and withdrawal periods must be observed in every market.
Periodic re-authorisation of feed additives in the EU requires updated safety data.
Prescription-only status of oral solutions and VFD rules for certain combinations govern how products are sold.
Profiles of 33 companies operating in the Halofuginone Market market, including revenue, employee count, and market positioning where available.
Showing 33 of 33 companies
Company Headquarters: Carros, Southeastern France, France Founded: 1968 Workforce: ~4825 Company Working: Virbac develops, manufactures, and markets a wide range of veterinary pharmaceutical products and has a market experience of more than fifty years and is one of the top 10 players in the global animal health market. It operates through the livestock and aquaculture business segments, and manufactures products including parasiticides, immunology, antibiotics/dermatology, specialties, equine, and specialized pet food. The company has a presence in more than 100 countries and generates more than 60% of its revenue from outside Europe. It has 11 manufacturing units in different countries and five fully equipped R&D facilities for the development of products.
3 interactive charts drawn from the Halofuginone Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Halofuginone Market By Physical Form
Global Halofuginone Market By Livestock
Global Halofuginone Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
